Genetic variation in interleukin‐28B locus is associated with spontaneous clearance of HCV in children with non‐1 viral genotype infection
Giuseppe Indolfi, Melissa Sambrotta, Maria Moriondo, Chiara Azzari, Massimo Resti – 14 June 2011
Efficient production of Fah‐null heterozygote pigs by chimeric adeno‐associated virus‐mediated gene knockout and somatic cell nuclear transfer
Raymond D. Hickey, Joseph B. Lillegard, James E. Fisher, Travis J. McKenzie, Sean E. Hofherr, Milton J. Finegold, Scott L. Nyberg, Markus Grompe – 14 June 2011 – Hereditary tyrosinemia type I (HT1) results in hepatic failure, cirrhosis, and hepatocellular carcinoma (HCC) early in childhood and is caused by a deficiency in the enzyme fumarylacetoacetate hydrolase (FAH). In a novel approach we used the chimeric adeno‐associated virus DJ serotype (AAV‐DJ) and homologous recombination to target and disrupt the porcine Fah gene.
Does adiponectin benefit steatotic liver transplantation?
Maria Elias‐Miro, Marta Massip‐Salcedo, Monica Jimenez‐Castro, Carmen Peralta – 10 June 2011 – Strategies for improving the viability of steatotic donor livers could increase the number of organs suitable for transplantation. There is evidence that adiponectin, the most abundant adipose‐specific adipokine, acts as an anti‐obesity and anti‐inflammatory hormone. Here we review the signaling pathways of adiponectin and the possible therapies based on adiponectin regulation that have been examined or applied clinically.
Reply:
James A. Thomas, John P. Iredale, Stuart J. Forbes – 10 June 2011
Cyclic adenosine 3′,5′‐monophosphate in rat steatotic liver transplantation
Monica B. Jimenez‐Castro, Arani Casillas‐Ramirez, Marta Massip‐Salcedo, Maria Elias‐Miro, Anna Serafin, Antoni Rimola, Juan Rodes, Carmen Peralta – 10 June 2011 – Numerous steatotic livers are discarded as unsuitable for transplantation (TR) because of their poor tolerance of ischemia/reperfusion (I/R). Cyclic adenosine 3′,5′‐monophosphate (cAMP)–elevating agents protect against I/R injury both in nonsteatotic livers that have been removed from non–heart‐beating donors and subjected to warm ischemia or cold ischemia (CIS) and in perfused, isolated livers.
2010 International consensus conference on liver transplantation for hepatocellular carcinoma: Texts of experts
Mickael Lesurtel, Pierre‐Alain Clavien – 7 June 2011
Region‐specific challenges for minimizing endemic donor‐transmitted infections
Sherif Beniameen Mossad – 7 June 2011
Patients' expectations and success criteria for liver transplantation
James R. Rodrigue, Douglas W. Hanto, Michael P. Curry – 7 June 2011 – Patient‐reported outcomes are important to consider when the relative success of liver transplantation (LT) is being evaluated. Our primary objective was to examine the expectations for LT and the criteria for its success across 4 domains of functioning (pain, fatigue, emotional distress, and interference with daily activities) from the perspective of patients who were wait‐listed for LT.
Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations
Elizabeth A. Pomfret, J. Peter A. Lodge, Federico G. Villamil, Mark Siegler – 7 June 2011
Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review
Evangelos Cholongitas, John Goulis, Evangelos Akriviadis, Geore V. Papatheodoridis – 7 June 2011 – A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identification of factors associated with post‐LT HBV recurrence in patients receiving HBIG and NUCs.